🇺🇸 FDA
Patent

US 8840868

Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles

granted A61KA61K49/16A61K49/1812

Quick answer

US patent 8840868 (Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles) held by The Regents of the University of Colorado, a Body Corporate expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Sep 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K49/16, A61K49/1812, A61K49/1863, A61K49/1866